Antidepressant drug effects and depression severity: a patient-level meta-analysis.

CONTEXT Antidepressant medications represent the best established treatment for major depressive disorder, but there is little evidence that they have a specific pharmacological effect relative to pill placebo for patients with less severe depression. OBJECTIVE To estimate the relative benefit of medication vs placebo across a wide range of initial symptom severity in patients diagnosed with depression. DATA SOURCES PubMed, PsycINFO, and the Cochrane Library databases were searched from January 1980 through March 2009, along with references from meta-analyses and reviews. STUDY SELECTION Randomized placebo-controlled trials of antidepressants approved by the Food and Drug Administration in the treatment of major or minor depressive disorder were selected. Studies were included if their authors provided the requisite original data, they comprised adult outpatients, they included a medication vs placebo comparison for at least 6 weeks, they did not exclude patients on the basis of a placebo washout period, and they used the Hamilton Depression Rating Scale (HDRS). Data from 6 studies (718 patients) were included. DATA EXTRACTION Individual patient-level data were obtained from study authors. RESULTS Medication vs placebo differences varied substantially as a function of baseline severity. Among patients with HDRS scores below 23, Cohen d effect sizes for the difference between medication and placebo were estimated to be less than 0.20 (a standard definition of a small effect). Estimates of the magnitude of the superiority of medication over placebo increased with increases in baseline depression severity and crossed the threshold defined by the National Institute for Clinical Excellence for a clinically significant difference at a baseline HDRS score of 25. CONCLUSIONS The magnitude of benefit of antidepressant medication compared with placebo increases with severity of depression symptoms and may be minimal or nonexistent, on average, in patients with mild or moderate symptoms. For patients with very severe depression, the benefit of medications over placebo is substantial.

[1]  N. Nicolson,et al.  Reduced Stress-Sensitivity or Increased Reward Experience: The Psychological Mechanism of Response to Antidepressant Medication , 2009, Neuropsychopharmacology.

[2]  S. Montgomery,et al.  Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial , 2008, International clinical psychopharmacology.

[3]  S. Montgomery,et al.  A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder , 2008, International clinical psychopharmacology.

[4]  M. Liebowitz,et al.  Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder* , 2008 .

[5]  Blair T. Johnson,et al.  Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration , 2008, PLoS medicine.

[6]  R. Rosenthal,et al.  Selective publication of antidepressant trials and its influence on apparent efficacy. , 2008, The New England journal of medicine.

[7]  M. Liebowitz,et al.  A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. , 2007, The Journal of clinical psychiatry.

[8]  B. Pitrosky,et al.  A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder , 2007, International clinical psychopharmacology.

[9]  杉浦 義典 読む 海外文献紹介(第37回)Dimidjian S et al "Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression"[成人の大うつ病に対する行動活性化,認知療法,抗うつ剤のランダム化比較試験] , 2007 .

[10]  N. DeMartinis,et al.  A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. , 2007, The Journal of clinical psychiatry.

[11]  K. Rickels,et al.  Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. , 2006, The Journal of clinical psychiatry.

[12]  David C. Atkins,et al.  Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. , 2006, Journal of consulting and clinical psychology.

[13]  David J. Kupfer,et al.  Size of Treatment Effects and Their Importance to Clinical Research and Practice , 2006, Biological Psychiatry.

[14]  M. Gastpar,et al.  Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. , 2006, Pharmacopsychiatry.

[15]  R. DeRubeis,et al.  Cognitive therapy vs medications in the treatment of moderate to severe depression. , 2005, Archives of general psychiatry.

[16]  M. Posternak,et al.  Is it time to replace the Hamilton Depression Rating Scale as the primary outcome measure in treatment studies of depression? , 2005, Journal of clinical psychopharmacology.

[17]  Nice Depression: management of depression in primary and secondary care , 2005 .

[18]  R. Bagby,et al.  The Hamilton Depression Rating Scale: has the gold standard become a lead weight? , 2004, The American journal of psychiatry.

[19]  R. Lipman,et al.  Drug effects and initial severity of symptomatology , 1965, Psychopharmacologia.

[20]  Kathryn A Sexton,et al.  Does elimination of placebo responders in a placebo run‐in increase the treatment effect in randomized clinical trials? A meta‐analytic evaluation , 2004, Depression and anxiety.

[21]  M. Berner [The treatment of major depression]. , 2004, Pharmazie in unserer Zeit.

[22]  M. Posternak,et al.  Symptom Severity and Exclusion From Antidepressant Efficacy Trials , 2002, Journal of clinical psychopharmacology.

[23]  John C. Markowitz,et al.  Treatment and Prevention of Depression , 2002, Psychological science in the public interest : a journal of the American Psychological Society.

[24]  Robyn M Leventhal,et al.  Severity of Depression and Response to Antidepressants and Placebo: An Analysis of the Food and Drug Administration Database , 2002, Journal of clinical psychopharmacology.

[25]  M. Hegel,et al.  Treatment of dysthymia and minor depression in primary care: a randomized trial in patients aged 18 to 59 years. , 2001, The Journal of family practice.

[26]  D. Dunner Acute and maintenance treatment of chronic depression. , 2001, The Journal of clinical psychiatry.

[27]  Michael B. First,et al.  Handbook of Psychiatric Measures , 2000 .

[28]  M. Demitrack,et al.  The Impact of Restrictive Entry Criterion During the Placebo Lead‐in Period , 2000, Biometrics.

[29]  R. Kohnen,et al.  Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. , 1999, BMJ.

[30]  S. Wessely,et al.  The efficacy of drug treatments for dysthymia: a systematic review and meta-analysis , 1999, Psychological Medicine.

[31]  M. Trivedi,et al.  Evidence Report: Treatment of Depression - Newer Pharmacotherapies , 1999 .

[32]  L. Stewart,et al.  Re: "Comparison of effect estimates from a meta-analysis of summary data from published studies and from a meta-analysis using individual patient data for ovarian cancer studies". , 1998, American journal of epidemiology.

[33]  M. Trivedi,et al.  Treatment of depression--newer pharmacotherapies. , 1998, Psychopharmacology bulletin.

[34]  I Olkin,et al.  Comparison of effect estimates from a meta-analysis of summary data from published studies and from a meta-analysis using individual patient data for ovarian cancer studies. , 1997, American journal of epidemiology.

[35]  Feiger Ad A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. , 1996, Psychopharmacology bulletin.

[36]  J. Ieni,et al.  Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. , 1996, The Journal of clinical psychiatry.

[37]  A. Feiger A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression. , 1996, Psychopharmacology bulletin.

[38]  D. Baldwin,et al.  Dysthymia: Options in Pharmacotherapy , 1995 .

[39]  L. Mynors-Wallis,et al.  Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care , 1995, BMJ.

[40]  M. Trivedi,et al.  Does a Placebo Run-In or a Placebo Treatment Cell Affect the Efficacy of Antidepressant Medications? , 1994, Neuropsychopharmacology.

[41]  T. Silverstone A multicentre comparative trial of moclobemide, imipramine and placebo in major depressive disorder , 1994, International clinical psychopharmacology.

[42]  S. Dager,et al.  Chronicity of depressive episode in relation to antidepressant-placebo response. , 1991, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[43]  A. Nardi,et al.  Moclobemide, imipramine and placebo in the treatment of major depression , 1990, Acta psychiatrica Scandinavica. Supplementum.

[44]  J. Guelfi,et al.  Efficacy of reversible inhibitors of monoamine oxidase‐A in various forms of depression , 1990, Acta psychiatrica Scandinavica. Supplementum.

[45]  D. Robinson,et al.  Placebo-controlled dose-ranging trial designs in phase II development of nefazodone. , 1990, Psychopharmacology bulletin.

[46]  S D Imber,et al.  National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments. , 1989, Archives of general psychiatry.

[47]  M. Versiani,et al.  A Double-blind Comparative Trial of Moclobemide v. Imipramine and Placebo in Major Depressive Episodes , 1989, British Journal of Psychiatry.

[48]  E. Paykel,et al.  Double-blind placebo-controlled trial of amitriptyline among depressed patients in general practice. , 1988, The Journal of the Royal College of General Practitioners.

[49]  E. Giller,et al.  Assessing treatment response to the monoamine oxidase inhibitor isocarboxazid. , 1984, The Journal of clinical psychiatry.

[50]  Lofepramine and imipramine in unipolar depressed outpatients , 1982 .

[51]  K. Rickels,et al.  Trazodone in depressed outpatients. , 1982, The American journal of psychiatry.

[52]  K. Rickels,et al.  Lofepramine and imipramine in unipolar depressed outpatients. A placebo controlled study. , 1982, Acta psychiatrica Scandinavica.

[53]  L. Benjamin Statistical Treatment of the Law of Initial Values (LIV) in Autonomic Research: A Review and Recommendation , 1963, Psychosomatic medicine.

[54]  M. Hamilton A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.